title: Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?
authors.affiliation: Michigan State University, East Lansing, USA. weismantel@ht.msu.edu
authors.forename: D
authors.initials: D
authors.lastname: Weismantel
authors.forename: P
authors.initials: P
authors.lastname: Danis
mesh_terms: D000924:Anticholesteremic Agents / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring / Q000379:methods*; D019317:Evidence-Based Medicine; D015248:Gemfibrozil / Q000009:adverse effects*; D006801:Humans; D008111:Liver Function Tests / Q000592:standards*; D009135:Muscular Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000378:metabolism; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D013997:Time Factors; D000637:Transaminases / Q000097:blood*
chemical_list: D000924:Anticholesteremic Agents; D000637:Transaminases; D015248:Gemfibrozil